FocusRegulatory Science

Protein Replacement Therapies for Rare Diseases: A Breeze for Regulatory Approval?

Science Translational Medicine  27 Mar 2013:
Vol. 5, Issue 178, pp. 178fs10
DOI: 10.1126/scitranslmed.3005007

You are currently viewing the abstract.

View Full Text

Abstract

Protein replacement therapies for rare monogenic diseases have a higher probability of regulatory approval compared with biologics, small molecules, and grant-funded orphan drugs.

View Full Text